2600MO Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer.
Saved in:
| Title: | 2600MO Relevance of the CPS score and tumor nephrectomy in the SUNNIFORECAST trial comparing ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer. |
|---|---|
| Authors: | Bergmann, L.1 (AUTHOR), Albiges, L.2 (AUTHOR), Ahrens, M.3 (AUTHOR), Gross Goupil, M.4 (AUTHOR), Boleti, E.5 (AUTHOR), Gravis, G.6 (AUTHOR), Flechon, A.7 (AUTHOR), Grimm, M-O.8 (AUTHOR), Bedke, J.9 (AUTHOR), Barthelemy, P.10 (AUTHOR), Castellano Gauna, D.E.11 (AUTHOR), Mellado Gonzalez, B.12 (AUTHOR), Ivanyi, P.13 (AUTHOR), Floercken, A.14 (AUTHOR), Suarez Rodriguez, C.15 (AUTHOR), Maroto Rey, J.P.16 (AUTHOR), Gruenwald, V.17 (AUTHOR), Burkholder, I.18 (AUTHOR), Hartmann, A.19 (AUTHOR), Haanen, J.B.A.G.20 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1394-S1395. 2p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
